Summary
Global Markets Direct’s, ‘Treatment Resistant Depression - Pipeline Review, H1 2016’, provides an overview of the Treatment Resistant Depression pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression
- The report reviews pipeline therapeutics for Treatment Resistant Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Treatment Resistant Depression therapeutics and enlists all their major and minor projects
- The report assesses Treatment Resistant Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Treatment Resistant Depression
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Treatment Resistant Depression
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Treatment Resistant Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Axsome Therapeutics, Inc.
Johnson & Johnson
Otsuka Holdings Co., Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Treatment Resistant Depression Overview 7
Therapeutics Development 8
Pipeline Products for Treatment Resistant Depression - Overview 8
Pipeline Products for Treatment Resistant Depression - Comparative Analysis 9
Treatment Resistant Depression - Therapeutics under Development by Companies 10
Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes 11
Treatment Resistant Depression - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Treatment Resistant Depression - Products under Development by Companies 15
Treatment Resistant Depression - Products under Investigation by Universities/Institutes 16
Treatment Resistant Depression - Companies Involved in Therapeutics Development 17
Addex Therapeutics Ltd 17
Amorsa Therapeutics Inc. 18
Axsome Therapeutics, Inc. 19
Johnson & Johnson 20
Otsuka Holdings Co., Ltd. 21
Treatment Resistant Depression - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 31
(bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
(dextromethorphan + quinidine sulfate) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AMS-410 FA - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AMS-520 ER - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AVP-786 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
esketamine hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EVT-100 Series - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
EVT-103 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
riluzole - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
VU-0431316 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Treatment Resistant Depression - Recent Pipeline Updates 49
Treatment Resistant Depression - Dormant Projects 59
Treatment Resistant Depression - Discontinued Products 60
Treatment Resistant Depression - Product Development Milestones 61
Featured News & Press Releases 61
Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression 61
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 61
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Number of Products under Development for Treatment Resistant Depression, H1 2016 8
Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H1 2016 17
Treatment Resistant Depression - Pipeline by Amorsa Therapeutics Inc., H1 2016 18
Treatment Resistant Depression - Pipeline by Axsome Therapeutics, Inc., H1 2016 19
Treatment Resistant Depression - Pipeline by Johnson & Johnson, H1 2016 20
Treatment Resistant Depression - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Assessment by Combination Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 30
Treatment Resistant Depression Therapeutics - Recent Pipeline Updates, H1 2016 49
Treatment Resistant Depression - Dormant Projects, H1 2016 59
Treatment Resistant Depression - Discontinued Products, H1 2016 60
List of Figures
Number of Products under Development for Treatment Resistant Depression, H1 2016 8
Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 22
Assessment by Combination Products, H1 2016 23
Number of Products by Top 10 Targets, H1 2016 24
Number of Products by Stage and Top 10 Targets, H1 2016 24
Number of Products by Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Routes of Administration, H1 2016 28
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Stage and Molecule Types, H1 2016 30
